Investors & Partners

Capitalizing on a validated modality and a monogenic driver.

Monogenic Driver

ASPS is driven by a single fusion protein (ASPSCR1-TFE3), reducing biological risk compared to complex polygenic cancers.

Validated Modality

Targeted Protein Degradation (TPD) is a proven clinical modality, unlocking "undruggable" transcription factors like TFE3.

Capital Efficient

Our virtual, agentic model eliminates fixed lab costs, directing capital straight to asset generation and validation.

Request Data Room Access

Qualified investors may request access to our Virtual Data Room (VDR) containing full preclinical data and IP strategy.

Access is granted at the discretion of Sarkome management.

News & Updates

Updates on patent filings and advisory board appointments coming soon.